SCHEMBL6531979

SCHEMBL6531979

CCCCCN1CC(c2ccccc2)CC1=O

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.60
TSHR P16473 1/20 0.60
BRD4 O60885 4/20 0.58
TP53 P04637 2/20 0.51
CHRM2 P08172 1/20 0.51
CHRM4 P08173 1/20 0.51
CHRM5 P08912 1/20 0.51
CHRM1 P11229 1/20 0.51
CHRM3 P20309 1/20 0.51
LMNA P02545 1/20 0.48
PKM P14618 1/20 0.48
GRM2 Q14416 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
PLA2G7 Q13093 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ALDH1A1 P00352 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28905044 0.99 HPGD (0.58) HPGDTSHRBRD4TP53CHRM2
Hydrochloric Acid SCHEMBL28741368 0.97 HPGD (0.57) HPGDTSHRBRD4TP53CHRM2
SCHEMBL7402106 0.95 HPGD (0.61) HPGDTSHRBRD4TP53CHRM2
SCHEMBL10755797 0.89 HPGD (0.65) HPGDTSHRBRD4TP53CHRM2
SCHEMBL10762307 0.83 HPGD (0.69) HPGDTSHRBRD4TP53CHRM2
SCHEMBL13532862 0.83 HPGD (0.69) HPGDTSHRBRD4TP53CHRM2
SCHEMBL10940620 0.79 HPGD (0.60) HPGDTSHRBRD4TP53CHRM2
SCHEMBL15387818 0.79 DRD2 (0.52) HPGDTSHRBRD4CHRM2CHRM4
SCHEMBL14560487 0.77 ADRA1D (0.56) BRD4GRM2MEN1KMT2ASMN1; SMN2
SCHEMBL11472575 0.76 TSHR (0.69) HPGDTSHRBRD4TP53CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0439766-A2 Process for the preparation of N-acyl-4-phenyl-pyrrolidin-2-ones having cerebroprotective activity ARZNEIMITTELWERK DRESDEN GmbH (DE) 1991-08-07 EP claimed
JP-5032622-A None JP disclosed
US-20050032858-A1 Novel heterocyclic compound and anti-inflamatory agent NIPPON SODA CO., LTD. (JP) 2005-02-10 US disclosed
EP-1435353-A1 NOVEL HETEROCYCLIC COMPOUND AND ANTI-INFLAMMATORY AGENT NIPPON SODA CO., LTD. (JP) 2004-07-07 EP disclosed
US-5441973-A Treating cerebral functional disorders; nootropic agents ARZNEIMITTELWERK DRESDEN G.M.B.H. (DE) 1995-08-15 US disclosed
US-5441973-A Treating cerebral functional disorders; nootropic agents ARZNEIMITTELWERK DRESDEN G.M.B.H. (DE) 1995-08-15 US disclosed
JP-H0532622-A PREPARATION OF N-ACYL-4-PHENYL-PYRROLIDIN-2-ONE HAVING CEREBROPROTECTIVE EFFECT ARZNEIMITTELWERK DRESDEN GMBH 1993-02-09 JP disclosed
EP-0439766-A2 Process for the preparation of N-acyl-4-phenyl-pyrrolidin-2-ones having cerebroprotective activity ARZNEIMITTELWERK DRESDEN GmbH (DE) 1991-08-07 EP disclosed
EP-0439766-A2 Process for the preparation of N-acyl-4-phenyl-pyrrolidin-2-ones having cerebroprotective activity ARZNEIMITTELWERK DRESDEN GmbH (DE) 1991-08-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032858-A1 Novel heterocyclic compound and anti-inflamatory agent TLR5, IRF3, IL4 HPGD 440/4885TSHR 4257/4885BRD4 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.